Home›Iomeprol Injection

Iomeprol Injection

Also known as: Iomervu

Radiographic Contrast AgentX-Ray Contrast Activity

Route: Intra-Arterial, Intravenous

2 interactions on record⛔ Black Box Warning

Iomeprol Injection has 2 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Metformin, Radioactive Iodine. Patients taking Iomeprol Injection should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Major: 1
Moderate: 1

Major (1)

Iomeprol Injection + Metformin— Stop metformin at or prior to IOMERVU administration in patients with eGFR 30-60 mL/min/1.73m², hepatic impairment, alco…

Moderate (1)

Iomeprol Injection + Radioactive Iodine— Avoid thyroid therapy or testing using radioactive iodine for up to 6 weeks post-IOMERVU. IOMERVU may interfere with thy…

Iomeprol Injection + Metformin⚠️Major

Stop metformin at or prior to IOMERVU administration in patients with eGFR 30-60 mL/min/1.73m², hepatic impairment, alcoholism, or heart failure. Iodinated contrast agents increase risk of metformin-induced lactic acidosis through worsening renal function.

Iomeprol Injection + Radioactive Iodine🟡Moderate

Avoid thyroid therapy or testing using radioactive iodine for up to 6 weeks post-IOMERVU. IOMERVU may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy.

⛔ FDA Black Box Warning

WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only. (2.1, 5.1)

Contraindications

4 CONTRAINDICATIONS None. None ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary Available data from literature and postmarketing reports on iomeprol use in pregnant women over decades have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental outcomes were observed with intravenous administration of iomeprol to pregnant rats and rabbits at doses up to 0.45-times the maximum recommended human dose of 86,000 mg iodine. Animal studies show that iomeprol crosses the placenta ( see Data ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Embryo-fetal developmental toxicity studies were performed with intravenous administration of iomeprol in rats at daily doses of 600 mg, 1,500 mg, or 4,000 mg iodine/kg (0.07-, 0.17- or 0.45-fold the human equivalent dose (HED, mg/m 2 ) using the maximum human dose of 86,000 mg iodine per administration) from gestation days (GD) 6 to 15 and in rabbits at daily doses of 300 mg, 800 mg, or 2,000 mg iodine/kg (0.07-, 0.18- or 0.45-fold the HED using the maximum human dose of 86,000 mg iodine per administration) from GD 6 to 18. Iomeprol did not result in fetal harm at the highest doses evaluated, 0.45-times the maximum recommended human dose of 86,000 mg iodine. A biodistribution study with a single intravenous administration of 1,000 mg iodine/kg (0.11-fold the HED using the maximum human dose of 86,000 mg iodine per administration) of radiolabeled iomeprol to pregnant rats showed that iomeprol crosses the placenta. No accumulation of radioactivity in fetal tissues was observed.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.